New drug duo aims to slow aggressive stomach cancer
NCT ID NCT06487221
Summary
This study is testing whether a combination of two oral drugs, avutometinib and defactinib, can help people live longer and slow the growth of a specific, hard-to-treat type of stomach cancer that has spread. It is for adults whose cancer has continued to grow despite prior chemotherapy. The main goal is to see if the treatment can keep the cancer from getting worse for at least six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.